VACCINES TARGETING HUMAN AND ANIMAL
In annals of medical history, vaccines are unsurpassed in their impact for reducing some of the worst diseases afflicting human and animal health. The potential economic advantage of a vaccine vs. a drug in controlling the target disease globally has been demonstrated repeatedly.
Vaccinology is an art and a science. At TM3, we unlock the potential of the pathogen to generate a highly immunogenic particle as a vaccine. Our expertise include:
• Generation of live attenuated temperature-sensitive virus vaccines
• Completely inactivated, whole virion vaccines using TM3 Therapeutics proprietary technology
TM3 has developed a proprietary technology that creates whole inactivated viruses as vaccines. A whole inactivated immunogen has been proven to elicit far better immune responses than either sub-unit, or fragmented immunogen. Generation of cellular and humoral immunity needs to be complemented by efficient antigen processing and presentation, as well as activation of the innate immune responses. TM3 vaccine technology enhances the capacity for all three arms of the immune response, leading to a more robust immune response. Our technology is a platform technology. We can inactivate enveloped and non-enveloped viruses, bacteria, and potentially cells as well, to generate vaccines targeting viruses, bacteria, and cancers.
TM3 has the technical capability to develop live attenuated viruses, using traditional methods and advanced molecular virology techniques. For example, we have created a live attenuated Human Rhino Virus (HRV). Our vision is to create a combination vaccine that encompasses many of the etiologic agents of the cold, in one single shot. HRV combined with Influenza, constitute greater than 90% of the colds worldwide. Viruses that lead to upper and lower respiratory infections have been implicated in exasperating Chronic Obstructive Pulmonary Diseases (COPD). The economic and social impact of this combination vaccine could be enormous.
Our facility includes a USDA certified BSL-2+ laboratory, a BSL-1 laboratory and an Assay laboratory. We are confident that our experience, expertise and capabilities in creating vaccines will dramatically accelerate your vaccine research and development project and intellectual property portfolio.